KRAS and cancer: In summary, in this study we found that, in addition to inhibiting oncogenic KRAS signaling, clinically-approved KRAS-G12C inhibitors also function as electrophilic inducers of NRF2, the activation of which promotes anti-cancer immunity through multiple parallel pathways, and thus positively contributes to the clinical efficacy of these anti-cancer drugs.